Taiwan - Delayed Quote TWD

Apex Biotechnology Corp. (1733.TW)

30.10
-0.25
(-0.82%)
At close: May 9 at 1:30:09 PM GMT+8
Loading Chart for 1733.TW
  • Previous Close 30.35
  • Open 29.95
  • Bid 30.10 x --
  • Ask 30.15 x --
  • Day's Range 29.95 - 30.40
  • 52 Week Range 26.40 - 36.25
  • Volume 137,222
  • Avg. Volume 355,091
  • Market Cap (intraday) 3.009B
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) 23.70
  • EPS (TTM) 1.27
  • Earnings Date --
  • Forward Dividend & Yield 1.10 (3.65%)
  • Ex-Dividend Date May 17, 2024
  • 1y Target Est --

Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemosmart gold hemoglobin screening systems. It also provides pesticide residue check systems; and care management and tele-health services. The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.

www.apexbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1733.TW

View More

Performance Overview: 1733.TW

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1733.TW
0.00%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
9.20%

1-Year Return

1733.TW
12.62%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.72%

3-Year Return

1733.TW
23.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
30.32%

5-Year Return

1733.TW
60.36%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
91.86%

Compare To: 1733.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1733.TW

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    3.03B

  • Enterprise Value

    2.60B

  • Trailing P/E

    23.90

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.65

  • Price/Book (mrq)

    1.66

  • Enterprise Value/Revenue

    1.40

  • Enterprise Value/EBITDA

    11.74

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.91%

  • Return on Assets (ttm)

    3.40%

  • Return on Equity (ttm)

    7.07%

  • Revenue (ttm)

    1.85B

  • Net Income Avi to Common (ttm)

    128M

  • Diluted EPS (ttm)

    1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    598.78M

  • Total Debt/Equity (mrq)

    6.74%

  • Levered Free Cash Flow (ttm)

    254.23M

Research Analysis: 1733.TW

View More

Company Insights: 1733.TW

Research Reports: 1733.TW

View More

People Also Watch